China's Linuo Pharmaceutical Packaging said its Brazil production facility is expected to begin operations within 2026 and that it has signed a construction agreement for a new site in Egypt, moves aimed at easing overseas capacity constraints. The glass packaging maker also reported H1 2026 revenue of CNY 673m (USD 100m), up 34.93% year on year, while net profit attributable to the parent fell 23.95% to CNY 31m (USD 4.6m) on e-commerce brand investment and share-based payment charges. Overseas revenue more than doubled to CNY 215m (USD 32m).
Why this mattersNew Brazil and Egypt capacity signals a Chinese pharma-glass exporter building local supply as overseas demand outpaces margins.
- Brazil production facility expected to begin operations within 2026
- Construction agreement signed for a new site in Egypt
- H1 2026 revenue CNY 673m (USD 100m), up 34.93% year on year
- Overseas revenue CNY 215m (USD 32m), up 115.02% year on year
- Net profit attributable to parent CNY 31m (USD 4.6m), down 23.95% year on year
- Heat-resistant glass segment revenue CNY 436m (USD 65m), up 53.36%
Shandong Linuo Pharmaceutical Packaging, listed on Shenzhen's ChiNext since November 2021, filed on 28 September 2026 for a main-board listing on the Hong Kong Stock Exchange, with China Merchants Securities International and Lego Financial Group as joint sponsors. The borosilicate glass maker ranks ninth in China's pharmaceutical glass packaging market and first in China, second globally, in daily-use heat-resistant glass. Proceeds are earmarked for industrialising semiconductor packaging glass substrates and RTU and PFS production.
Why this mattersA dual listing would give a leading Chinese borosilicate glass packaging player fresh capital to scale semiconductor glass substrates, a potential new growth line adjacent to pharma packaging.
- Filed for Hong Kong main-board listing on 28 September 2026, already listed on Shenzhen ChiNext since 11 November 2021
- Ranked 9th in China's pharmaceutical glass packaging market with 2.4% share by 2025 revenue, per Frost & Sullivan
- Ranked 1st in China and 2nd globally in daily-use heat-resistant glass, with 9.5% domestic and 5.1% global market share
- 2025 revenue was USD 146.4m (RMB 981.5m), down from USD 161.2m (RMB 1,080.8m) in 2024
- 2025 net profit was USD 5.9m (RMB 39.7m), down from USD 9.9m (RMB 66.1m) in 2024
- IPO proceeds earmarked for industrialising semiconductor packaging glass substrates and RTU and PFS production plus R&D
- Adjusted net profit for H1 2026 rose 11.9% to USD 6.8m (RMB 45.837m), even as reported net profit fell 23.9% to USD 4.7m (RMB 31.157m).
Shandong Linuo Pharmaceutical Packaging, already listed in Shenzhen as Linuo Packaging (301188.SZ), filed on 28 September 2026 for a dual Main Board listing on the Hong Kong Stock Exchange. The borosilicate glass specialist ranks second globally in heat-resistant glass for daily use with a 5.1% share and ninth in China's pharmaceutical glass packaging market. The listing filing coincides with the company's move into glass substrates for semiconductor packaging, where a pilot furnace was ignited in June 2026.
Why this mattersA dual listing would give a top-two global heat-resistant glass maker fresh capital access as it diversifies into semiconductor-grade glass substrates.
- Shandong Linuo Pharmaceutical Packaging (301188.SZ, listed in Shenzhen) filed on 28 September 2026 for a Main Board listing on the Hong Kong Stock Exchange.
- China Merchants Securities International and Lego Financial Group are joint sponsors of the HKEX listing.
- The company ranks second globally in heat-resistant glass for daily use, with a 5.1% market share, and first in China with 9.5% share, per Frost & Sullivan 2025 data.
- It ranks ninth among China pharmaceutical glass packaging suppliers, with a 2.4% market share.
- Products are sold to customers in about 60 countries across the Americas, Asia and Europe.
- A pilot furnace for glass substrates used in semiconductor packaging was ignited in June 2026, with sample provision to industry participants under way.